Abstract

SILVIA, Díaz Cerezo  and  MARTIN NUNEZ, Iker. Budgetary impact of a smoking cessation programme within companies. Med. segur. trab. [online]. 2009, vol.55, n.216, pp.46-55. ISSN 1989-7790.

Objective: To estimate the budgetary impact of a smoking cessation programme in a company. Methods: A model was developed to simulate a 1000-employee company, with a time horizon of 3 years. 26% of smoking prevalence was considered; 70% of smokers would be willing to quit (published national data). The smoking cessation rates where obtained from clinical trials (21% for varenicline, 13% for bupropion, 12% for NST and 7% for advice/counselling) and it was considered that the 25% of the smokers would take each of the therapies. The costs derived from the programme (treatment and initiation/counselling) and the savings due to the improvement in the work absenteeism and productivity were included. Results: The investment that the company would need for starting up the program (€54,794) would be almost recovered in one year. After the third year, the total savings for the company would rise to €85,445; €4,092 for each employee who achieves to quit smoking. Conclusions: The implementation of a smoking cessation programme would result in health benefits for the employees as well as savings for the company after the first year.

Keywords : Varenicline; budgetary impact; companies; smoking cessation.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )